Novelix Pharma Surges on Turnaround, Raises ₹13.9 Cr via Preferential Issue

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAditi Singh|Published at:
Novelix Pharma Surges on Turnaround, Raises ₹13.9 Cr via Preferential Issue
Overview

Novelix Pharmaceuticals Limited, formerly Trimurti Limited, has reported a dramatic turnaround in its Q3 FY26 results, with income from operations skyrocketing by 790% year-on-year to ₹4,840.25 Lakhs. The company posted a net profit of ₹100.44 Lakhs, a significant shift from a net loss last year. Concurrently, it successfully raised ₹13.92 Crores through a preferential issue of 23.20 lakh equity shares at ₹60 each, strengthening its capital base for a strategic pivot.

Novelix Pharmaceuticals Announces Robust Q3 Turnaround, Fuels Pharma Pivot with Capital Infusion

Novelix Pharmaceuticals Limited (formerly Trimurti Limited) has signaled a significant operational rebound with its unaudited financial results for the quarter ended December 31, 2025 (Q3 FY26). The company reported a staggering 790% year-on-year increase in income from operations, reaching ₹4,840.25 Lakhs, up from ₹529.98 Lakhs in the corresponding quarter of the previous fiscal year.

📉 The Financial Deep Dive

This revenue surge translated into a healthy net profit of ₹100.44 Lakhs for Q3 FY26, a marked improvement from the net loss of ₹7.65 Lakhs reported in Q3 FY25. Consequently, the Earnings Per Share (EPS) saw a substantial recovery, with Basic EPS standing at ₹0.58 and Diluted EPS at ₹0.85, compared to a negative ₹0.08 for both in the prior year's quarter.

The company also successfully completed a preferential issue, allotting 23,20,000 equity shares at ₹60 per share, raising ₹13.92 Crores. This private placement involved 36 investors and has increased the company's paid-up equity capital to ₹19.93 Crores from ₹17.61 Crores. This capital infusion is crucial for Novelix Pharmaceuticals as it solidifies its strategic shift towards the pharmaceutical sector, indicated by its recent name change from Trimurti Limited.

🚩 Risks & Outlook

While the operational performance is commendable, the announcement lacks specific forward-looking guidance, growth drivers, or identified risks from management. The substantial increase in equity capital through the preferential issue also introduces potential shareholding dilution, which investors will need to monitor. The success of its strategic pivot into pharmaceuticals will be the key determinant of future performance, requiring close observation of market penetration and product pipeline developments in the upcoming quarters.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.